Department of Gastrointestinal Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Medicine (Baltimore). 2023 Oct 27;102(43):e35732. doi: 10.1097/MD.0000000000035732.
Breast cancer (BRCA) is a common malignancy worldwide that is associated with a high mortality rate. Despite recent improvements in diagnosis and treatment, there is an urgent need to investigate the processes underlying cancer progression and identify novel prognostic indicators. Anoikis, which plays a role in the development of human malignant tumors, has been gaining increasing interest from researchers. However, the potential role of anoikis-related genes (ANRGs) in the advancement of BRCA remains unknown. In this study, we aimed to assess the predictive value of ANRGs in BRCA, construct a prognostic model based on ANRGs, and explore the tumor microenvironment in different prognostic score groups. This study utilized data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to collect clinical information and RNA sequencing data from patients with BRCA. Information on ANRGs was gathered from GeneCards and Harmonizome portals. A risk score model based on ANRGs was created using least absolute shrinkage and selection operator Cox (LASSO) regression analysis. Additionally, the study explored the tumor microenvironment and enriched pathways in different risk groups. Finally, a novel ANRG-based nomogram is developed. A total of 142 differentially expressed genes associated with survival were identified, of which 5 genes were selected to create the ANRG signature. The risk score based on this signature proved to be an independent prognostic factor. Further analysis revealed that different risk subgroups exhibited variations in the tumor microenvironment and drug sensitivities. Subsequently, a nomogram was developed using risk scores and clinicopathological factors. The decision curve analysis results suggest that patients with BRCA might derive clinical treatment benefits from utilizing this prognostic model. Based on the results of this study, the ANRG signature and nomograph established can be used for clinical decision-making in patients with BRCA.
乳腺癌（BRCA）是一种常见的恶性肿瘤，全球范围内死亡率较高。尽管近年来在诊断和治疗方面有所改善，但仍迫切需要研究癌症进展的相关过程并确定新的预后指标。在人类恶性肿瘤的发生发展中发挥作用的细胞凋亡，越来越受到研究人员的关注。然而，细胞凋亡相关基因（ANRGs）在 BRCA 进展中的潜在作用尚不清楚。在本研究中，我们旨在评估 ANRGs 在 BRCA 中的预测价值，构建基于 ANRGs 的预后模型，并探讨不同预后评分组的肿瘤微环境。本研究利用癌症基因组图谱（TCGA）和基因表达综合数据库（GEO）数据库的数据，从 BRCA 患者中收集临床信息和 RNA 测序数据。从 GeneCards 和 Harmonizome 门户收集 ANRGs 信息。使用最小绝对收缩和选择算子 Cox（LASSO）回归分析构建基于 ANRGs 的风险评分模型。此外，研究还探讨了不同风险组的肿瘤微环境和富集途径。最后，开发了一种新的基于 ANRG 的列线图。确定了与生存相关的 142 个差异表达基因，其中 5 个基因被选中用于创建 ANRG 特征。基于该特征的风险评分被证明是独立的预后因素。进一步分析表明，不同的风险亚组在肿瘤微环境和药物敏感性方面存在差异。随后，使用风险评分和临床病理因素开发了列线图。决策曲线分析结果表明，BRCA 患者可能从使用该预后模型中获得临床治疗获益。基于本研究的结果，建立的 ANRG 特征和列线图可用于 BRCA 患者的临床决策。
